Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Ablynx nv
Ablynx nv
Activities:
Regulatory
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Media
Sanofi completes acquisition of Ablynx
Sanofi has now acquired all outstanding shares, warrants and convertible bonds of Ablynx following the expiration of the Squeeze-out procedure
Research & Development
Sanofi to acquire Ablynx for €3.9 billion
The acquisition of Ablynx continues Sanofi's commitment to breakthrough innovation, focused on addressing multiple disease targets with single multi-specific molecules
Recruitment
Ablynx appoints Dr Robert Friesen as Chief Scientific Officer
Research & Development
Ablynx announces board changes
Finance
Ablynx appoints General Manager
Pharmaceutical
Ablynx appoints Markus Ewert as CBO
Research & Development
Novel Nanobody to begin clinical development in osteoarthritis
Ablynx to receive €15m milestone payment from Merck
Subscribe now